Comparative Study of the Mesenchymal Stem Cell and Simvastatin in the Treatment of Hepatic Fibrosis in Rats Induced by Carbon Tetrachloride

Document Type : Original Article

Authors

1 anatomy department faculty of medicen benha university

2 anatomy department, faculty of medicine, benha university

3 Professor & Head of Anatomy & Embryology ,Department , faculty of medicine, Benha University

4 Assistant Professor of Anatomy & Embryology, Faculty of medicine , Benha University

Abstract

Background: Hepatic fibrosis is an important medical disease with high rates of morbidity and mortality. Bone marrow mesenchymal stem cells have been recommended as a powerful therapy for treatment of liver fibrosis. Simvastatin has an ameliorative effect on fibrosis of different organs.
The study aimed at comparing between the effect of BM-MSCs and simvastatin in treatment of liver fibrosisinduced by CCL4.
Material and Methods: Fifty rats were categorized into, group I control group, group II in which rats injected by CCl4 to induce hepatic fibrosis. Group III in which rats were injected by CCL4,then injected intravenously by a single dose of BM-MSCs, group IV in which rats were injected by CCL4 then given simvastatin orally once daily for eight weeks. Group V in which rats were given both BM-MSC and simvastatin. At the end of the experimental study, blood samples were collected for biochemical analysis and liver tissues were prepared for histological and immunohistochemical examination.
Results: CCL4 significantly elevated liver enzymes and induced destruction of normal hepatic structures with significant elevation of mean area percentage of collagen fibers deposition and TGF-b expression. BM-MSC and simvastatin improved liver enzymes and histological structure of liver tissue, but the anti-fibrotic effect of BM-MSC was superior to that of simvastatin. Moreover, combination of BM-MSC and simvastatin exerted strong anti-fibrotic effect and preserved normal histologic structure of liver tissue more than each of them alone.
Conclusion: A combination of BM-MSCs and simvastatin has an ameliorative role in the treatment of liver fibrosis induced by CCl4.

Keywords

Benha Medical Journal
Volume 39, Special issue (Academic)
September and October 2022
Pages 78-95

Files

Share

How to cite

Statistics